The Supreme Court has questioned high pharmacy markups in hospitals, suggesting a 16% retail margin cap on all medicines. Following the bench's strong remarks, shares of major hospital chains including Apollo, Fortis, and Max Healthcare fell 4-6% as investors assessed the potential impact on pharmacy profitability.
The Indian Supreme Court has placed a spotlight on the pricing of medicines sold within hospital pharmacies, flagging the significant gap between the price paid to retailers and the final price charged to patients. During recent hearings, a bench comprising Justices Vikram Nath and Sandeep Mehta described these pricing disparities as a major concern, pointing to instances where the retail price of drugs reached up to 10 times the acquisition cost.
Proposed Margin Cap and Market Impact
To address these high costs, the Court has proposed that the government consider a uniform 16% cap on retail margins over the ‘Price to Retailer’ (PTR). Currently, such margin caps are limited to essential drugs under the Drugs (Prices Control) Order (DPCO) 2013. The Court’s suggestion to extend this 16% limit to all medicines has raised questions about how hospitals manage their pharmacy operations, which often serve as significant revenue and profit centers.
Following these judicial observations, shares of prominent hospital chains saw a decline. Stocks like Apollo Hospitals, Fortis Healthcare, and Max Healthcare witnessed a drop of 4-6% as the market reacted to the possibility of stricter regulatory controls on pharmacy markups. This reaction reflects investor concern that a mandated margin cap could lead to a reduction in the pharmacy segment’s contribution to overall hospital profitability.
Regulatory Context and Next Steps
The central government has acknowledged the issue of excessive pricing in the healthcare sector and has informed the Court that it is examining the situation to find a balanced solution. The government is expected to provide its formal response or a status report to the Supreme Court by October 12, 2026.
For investors, the key area of monitoring is the upcoming hearing and any subsequent regulatory directives. While the current discussion is centered on retail margins, the broader regulatory overhang persists regarding how hospital chains might be forced to alter their pricing models for in-house pharmacies. Furthermore, the Court’s concerns are also linked to the financial burden on government-funded schemes like Ayushman Bharat, which could add pressure on the authorities to enforce price controls more rigorously.
Investors may continue to track developments surrounding the October 12 hearing, as any move to standardize margins across all drug categories could influence the operational margins of hospital businesses. The situation highlights the ongoing regulatory and judicial focus on making healthcare services more affordable, which remains a factor impacting the sector's outlook.